CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine
CBIH links potential commercialization to research outcomes, regulatory requirements and successful commercial agreements.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cannabis Bioscience International Holdings (CBIH) announced an expanded research strategy linking endocannabinoid biology, personalized medicine and potentially patentable biomedical technologies.
The company plans to investigate how cannabinoids and the body's endocannabinoid system interact with cellular pathways involved in immune regulation, chronic pain, cancer biology and other conditions. It continues preparing scientific studies to develop potentially patentable technologies. Anticipating proposed federal marijuana rescheduling from Schedule I to Schedule III, CBIH intends to explore research opportunities, partnerships and licensing agreements. Potential therapeutic applications remain subject to scientific assessment, clinical validation and applicable regulatory requirements.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.CBIH plans expanded research into cannabinoid interactions with molecular and cellular disease pathways.
- Minor pointScientific studies remain in preparation to develop potentially patentable technologies and strengthen CBIH's intellectual property portfolio.
- Minor point. Forward-looking: it has not happened yet and may not happen.CBIH intends to explore research opportunities, partnerships and licensing agreements with medical, pharmaceutical and biotechnology organizations.
Negative
- Minor pointPotential therapeutic applications require scientific assessment, clinical validation and applicable regulatory compliance.
- Minor pointFederal marijuana rescheduling from Schedule I to Schedule III, anticipated in CBIH's research strategy, remains proposed.
- Minor point. Forward-looking: it has not happened yet and may not happen.CBIH's potential commercialization depends on research outcomes, regulatory requirements and successful commercial agreements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Houston, Texas--(Newsfile Corp. - October 19, 2026) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced an expansion of its scientific research strategy focused on the intersection of endocannabinoid biology, precision medicine, and the development of intellectual property with potential biomedical applications.
"We are witnessing a new era in the history of medicine: an era in which human biology plays a central role in the healing process. The future is no longer solely about treating diseases, but also about discovering how the human body itself can help us overcome them. Humans healing humans," stated Dr. Rosangel Andrades, M.D., CBIH's Director of Research and Development.
"Biological medicine as a personalized treatment approach seeks to use each patient's specific biological characteristics to select, adapt, or develop a more precise therapeutic strategy. This may involve analyzing biomarkers, genetic profiles, cells, antibodies, or other biological components to identify the mechanisms involved in a disease and select the most appropriate intervention. In certain advanced therapies, it is even possible to use a patient's own cells, modify or prepare them in a laboratory, and administer them back to the patient for a specific therapeutic purpose. As a result, medicine is evolving from treatments designed for the general population toward therapeutic strategies guided by each patient's individual biology."
CBIH plans to investigate how cannabinoids and the endocannabinoid system interact with molecular and cellular pathways associated with immune regulation, neuroinflammation, reproductive health, chronic pain, metabolic dysfunction, autoimmune diseases, cancer biology, and aging. The Company emphasized that any therapeutic applications arising from these investigations would remain subject to scientific assessment, clinical validation, and applicable regulatory requirements.
"Our objective is ambitious but clear: to investigate how endocannabinoid science may contribute to this transformation in biological medicine and open new possibilities for treating complex diseases. We believe that biological medicine represents not only the future of medicine, but also the future of humanity," stated Dr. Jennifer Salguero, a biologist with a Ph.D. in Science from the University of São Paulo, Brazil, and Chief Patent Officer of CBIH.
To advance its long-term strategy, CBIH continues preparing scientific studies to develop potentially patentable technologies and strengthen its intellectual property portfolio. Anticipating the proposed broader federal rescheduling of marijuana from Schedule I to Schedule III, the Company intends to explore new research opportunities, strategic partnerships, and licensing agreements with medical, pharmaceutical, and biotechnology organizations. CBIH believes these initiatives could drive future commercialization and long-term shareholder value, subject to research outcomes, regulatory requirements, and successful commercial agreements.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.x.com/CBIHIR/
Instagram: www.instagram.com/CBIHSTOCK
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319667
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is CBIH's expanded research strategy?
CBIH plans to investigate how cannabinoids and the endocannabinoid system interact with molecular and cellular pathways associated with disease and biological processes. Its research scope includes immune regulation, neuroinflammation, reproductive health, chronic pain, metabolic dysfunction, autoimmune diseases, cancer biology and aging.
Has CBIH validated therapeutic applications from its expanded research strategy?
Potential therapeutic applications arising from these investigations remain subject to scientific assessment, clinical validation and applicable regulatory requirements. CBIH continues preparing scientific studies aimed at developing potentially patentable technologies.